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Abstract: 
Background: The clinical presentation of European patients with mild-to-moderate Covid-19 
infection is still unknown. 
Objective: To study the clinical presentation of Covid-19 in Europe. 
Methods: Patients with positive diagnosis of Covid-19 were recruited from 18 European hospitals. 
Epidemiological and clinical data were obtained through a standardized questionnaire. Bayesian 
analysis was used for analyzing the relationship between outcomes.
Results: 1,420 patients completed the study (962 females, 30.7% of health care workers). The 
mean age of patients was 39.17±12.09 years. The most common symptoms were headache 
(70.3%), loss of smell (70.2%), nasal obstruction (67.8%), cough (63.2%), asthenia (63.3%), 
myalgia (62.5%), rhinorrhea (60.1%), gustatory dysfunction (54.2%) and sore throat (52.9%). 
Fever was reported by on 45.4%. The mean duration of Covid-19 symptoms of mild-to-moderate 
cured patients was 11.5±5.7 days. The prevalence of symptoms significantly varied according to 
age and sex. Young patients more frequently had ear, nose, and throat complaints, whereas elderly 
individuals often presented fever, fatigue and loss of appetite. Loss of smell, headache, nasal 
obstruction and fatigue were more prevalent in female patients. The loss of smell was a key 
symptom of mild-to-moderate Covid19 patients and was not associated with nasal obstruction and 
rhinorrhea. Loss of smell persisted at least 7 days after the disease in 37.5% of cured patients.
Conclusion: The clinical presentation of mild-to-moderate Covid-19 substantially varies 
according to the age and the sex characteristics of patients. Olfactory dysfunction seems to be an 
important underestimated symptom of mild-to-moderate Covid-19 that needs to be recognized as 
such by the WHO. 
Key words: covid-19; coronavirus; clinical; epidemiological; symptoms; Europe; patients; 
medicine.
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Introduction: 
Since the first case of pneumonia related to severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) [1], the coronavirus disease 2019 (Covid-2019) has spread rapidly worldwide. In 
Europe, the first cases have been identified in Italy, dating back January, 19, 2020 [2]. As of April 
4, a total of 840,246 European citizens have been diagnosed through laboratory testing, with 
70,583 corresponding deaths [3]. European data regarding clinical presentation and 
epidemiological factors of laboratory-confirmed Covid-2019 are limited by a paucity of diagnostic 
tests in many European countries. A recent study suggests 3 distinct variants of Covid-19, 
representing clusters of infection in the United States and Australia (Type A), China and East Asia 
(Type B) and Europe (Type C) [4].  
Therefore, it seems that there may be significant epidemiological differences between Asian and 
European disease regarding, for example, the spread rate of the disease and the mortality [5].  
The aim of this European multicenter study is to investigate the clinical and epidemiological 
characteristics of patients with mild-to-moderate Covid-2019 infection.
Materials and Methods: 
This observational study was initiated by the Covid-19 Task Force of the International Federation 
of Otorhinolaryngological Societies (World Otolaryngological Federation, YO-IFOS). At the 
onset of the pandemic, the European otolaryngologists of the Task force have started 
collaborations with Internal Medicine physicians, infectious diseases specialists, microbiologists 
and clinical biologists of their respective hospitals to conduct this multicenter study. The 
institutional ethics committees of five European Hospitals approved the study protocol (HAP2020-
011; CHUSP20032020; EpiCURA-2020-2303, CHUC,P20/30-24/03-B325-2020; J.Bordet 
Institute: CE3137). Patient informed consent was obtained electronically in light of the urgent 
need to collect data.
Data Collection 
More than 50 European physicians have collected clinical data from patients with laboratory-
confirmed Covid-19 infection. The data have been collected from March 22 to April 10 by 
physicians from 18 Hospitals from French (Paris, Marseille), Italian (Milan, Verona, Naples, 
Genova, Florence, Forli), Spanish (Sevilla, Santiago de Compostela, San Sebastian), Belgian A
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(Mons, Brussels, Charleroi, Saint-Ghislain), and Swiss (Geneva) cities. 
In these European centers, the nasal or throat swabs were made for the following patients: 1) 
patients suspected on the basis on a consultation in the family physician, 2) patients who consulted 
specialists (internal medicine physician, pulmonologist, cardiologist, otolaryngologist, etc.), and 3) 
patients admitted/consulting in the Emergency Department for mild-to-moderate complaints. 
The diagnosis of Covid-19 infection was based on the WHO interim guidance [6]. Viral RNA 
extraction was performed by m2000 mSample Preparation SystemDNA Kit (Abbott) using 1000µl 
manually lysed sample (700µl sample + 800µl lysis buffer from kit) eluted in 90µl elution buffer. 
A qRT-PCR internal control was added at each extraction. qRT-PCR was performed using 10µl of 
extracted sample in the RealStar®SARS-CoV-2 RT-PCR Kit from Altona-diagnostics with a cut-
off set at 40 Ct.
Patients with positive RT-PCR were identified through the database of the laboratories of the 
hospitals. The hospital admittance records were used to identify additional patients who realized 
the RT-PCR in an external Lab. Patients requiring intensive care admission were not included due 
to their health status and the inability to answer to the questions. Thus, we mainly included mild-
to-moderate Covid-19 patients, defined as patients without need of intensive care. To avoid some 
bias, the methodology was similar for all centers.
Study Outcomes 
The clinical and epidemiological outcomes data were obtained using a standardized questionnaire 
in the patient’s room; or over the phone for house-bound patients or infected health professionals. 
For confined patients, the same questionnaire was created with Professional Survey Monkey (San 
Mateo, California, USA), so that each participant could complete the survey only once. This 
online collection method allowed the automatic extraction of data, simplifying the realization of 
statistic matrixes. Note that investigators had access to the medical records of hospitalized patients 
for completing some data (comorbitities). 
The selection of the relevant epidemiological and clinical features included in the questionnaire 
was carried out by the Covid-19 Task Force members. These included demographic data, medical 
history, tobacco addiction, comorbidities, general symptoms, otolaryngological symptoms, and 
treatments. The disease onset was defined as the first day of symptoms. The length of symptoms 
was defined as the number of days where the patients had >1 general or ear, nose and throat 
symptoms associated with the Covid-19 infection. The length of the disease was assessed on A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
patients who have a resolution of general symptoms for at least a week. 
Statistical Methods 
Bayesian networks used in the present study included a qualitative model based on Directed 
Acyclic Graph (DAG) indicating the dependencies, and a quantitative model based on local 
probability distributions, specifying the probabilistic relationships [7]. DAG consisted of nodes 
and directed links. Nodes were variables on interest, such as loss of smell, sex, age, whereas 
directed links represented statistical dependencies among the variables. 
The local probability distributions were either marginal, for nodes without incoming links, or 
conditional, for nodes with incoming links. In this case, the dependencies were quantified by 
conditional probability tables (CPT) for each node given the nodes associated with the incoming 
links in the graph. Once fully specified, a Bayesian network compactly represented the joint 
probability distribution (JPD) and, thus, was used for computing the posterior probabilities of any 
subset of variables given evidence about any other subset. The Bayesian networks presented in 
this article were machine learned with BayesiaLab (Changé, France, Europe). The algorithms 
minimized the Minimum Description Length (MDL) score. Basically, the MDL score manages the 
trade-off between complexity and information, allowing the addition of arcs only when the 
additional cost in model representation is offset by the reduction in uncertainty.
Results: 
Demographic data
We collected the data of 1,566 patients over the study period, including 1,420 patients who 
completed the full evaluation (962 females). The mean age of patients was 39.17 ± 12.09 years 
(median: 37.00) ; 94% of those patients were under 60 years of age. The cohort included 436 
health care workers (30.7 % of cohort). Irrespective to the country, less than 10% of patients 
required hospitalization (N=116). The main ethnicities represented in our cohort were 
European/caucasian (91.4%), and, in lower proportions, North African (2.9%) and South 
American (2.6%) (Table 1). 
Clinical outcomes
SymptomsA
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The most prevalent symptoms were headache (70.3%), loss of smell (70.2%), nasal obstruction 
(67.8%), cough (63.2%), asthenia (63.3%), myalgia (62.5%), rhinorrhea (60.1%), gustatory 
dysfunction (54.2%) and sore throat (52.9%) (Table 1, Figure 1). Fever was reported by on 45.4%. 
Some patients added the following: conjunctivitis (N=9), visual acuity reduction (N=6), rotatory 
vertigo (N=6), tinnitus (N=5), cutaneous rash (N=4), cervical lymphadenopathies (N=2), and 
parotiditis (N=1). The mean duration of Covid-19 symptoms of mild-to-moderate cured patients 
(N=264) was 11.5 ± 5.7 days (Figure 2). 
Comorbidities 
Allergic rhinitis (13.4%), hypertension (9.2%), gastroesophageal reflux disease (6.9%) and asthma 
(6.5%) were the most prevalent comorbidities (Table 1). 
Age
The Bayesian analysis revealed that prevalence of symptoms significantly varied according to age. 
The clinical presentation of young Covid-19 patients more frequently included ear, nose, and 
throat symptoms, i.e. loss of smell, nasal obstruction, rhinorrhea, facial pain, headache, throat 
pain, compared with elderly individuals, who more frequently presented fever, fatigue, loss of 
appetite and diarrhea (p<0.010). 
Sex
The following symptoms were proportionally more prevalent in females compared with males: 
loss of smell, headache, nasal obstruction, throat pain and fatigue (p<0.001). Males more 
frequently suffered from cough and fever (p<0.001). There was no significant difference in the 
duration of the disease regarding sex. 
Key Symptoms
The Bayesian analysis identified that loss of smell is a key symptom in Covid-19 infection (Figure 
3). Loss of smell was significantly influenced by both sex and age of patients. Excluding patients 
with current or history of chronic rhinosinusitis, 29.4% and 38.5% of patients with loss of smell 
had no nasal obstruction or rhinorrhea, respectively. Similarly, dysgeusia, which was defined as 
partial or total loss of the following four taste modalities: salty, sweet, bitter and sour, was more 
frequently found in young patients and in female patients (p=0.001). Gustatory dysfunction was A
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present in 23.4%, 49.8%, and 61.6% of patients without smell disorder, partial and total loss of 
smell, respectively. A total of 429 patients did not have gustatory dysfunction but had olfactory 
disorders (30.2%). According to the Bayesian analysis, the developments of olfactory and 
gustatory dysfunctions were linked (p<0.001), while many patient patterns have been identified 
regarding the development of one or both dysfunctions. 
Among cured patients, 37.5% (N=99) reported that olfactory dysfunction persisted at least 7 days 
after the end the disease. The mean duration of loss of smell within the patients who recovered 
olfaction was 8.41 ± 5.05 days. The recovery of olfaction was not significantly linked to recovery 
of taste.
Treatment outcomes
The majority of patients received oral treatment for the Covid-19 infection (N=1005; 70.8%) 
whereas 29.1% of patients did not receive any treatment. Depending on the symptoms, patients 
received analgesic drugs (e.g. paracetamol (86.1%), nonsteroidal anti-inflammatory drugs (7.3%)), 
oral corticosteroids (1.4%), mucolytics (8.7%), hydroxychloroquine (12.4%), antibiotics (e.g. 
macrolides (3.1%) and beta-lactam antibiotic (4.5%)), and antiviral drugs (1.1%). Pulmonary 
aerosols and nasal treatments have been used in 2.2% and 9.4% of cases, respectively. 
Discussion: 
The majority of patients with Covid-19 infection are thought to be paucisymptomatic and do not 
require hospitalization. These patients remain potentially infectious individuals who must be 
identified and confined in order to reduce transmission. To date, there is no clinical study 
describing the epidemiological and clinical features of European mild-to-moderate Covid-19 
patients. 
The clinical presentation of mild-to-moderate patients in Europe mainly consists of headache 
(70.3%), loss of smell (70.2%), nasal obstruction (67.8%) and asthenia (63.3%). Interestingly, 
young patients presented more frequently with ear, nose, and throat symptoms than the elderly. 
The European clinical presentation appears different from that reported in Asian. According to 
recent studies, the Covid-19 infection of both hospitalized and non-hospitalized patients in Asia 
was mainly associated with fever, cough, dyspnea, and fatigue [8-12]. Precisely, in the study of 
Huang et al., the most prevalent symptoms were fever (98%), cough (76%) and dyspnea (55%) 
[8]. The authors only included hospitalized patients. In the study of Zou et al., the main prevalent A
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symptoms of hospitalized patients were fever (94%) and cough (79%) [10]. The symptom 
presentation appeared to be similar among elderly Asian patients with fever, cough and dyspnea as 
the most prevalent complaints [13]. Interestingly, Wu et al. provided substantial information about 
the proportion of mild-to-moderate patients in China, accounting for 81% of covid-19 patients but 
they did not study the clinical presentation of these patients [9]. Note that according to the China 
regions, 3.8 to 63.0% of infected patients were health care workers [9]. Surprisingly, only one 
Asian study reported olfactory and gustatory dysfunctions, accounting for 5.1% and 5.8% of 
patients, respectively [14]. The differences between our data and the Asian population may be 
explained by three main hypotheses. First, the Asian studies only included hospitalized patients 
who were probably more affected by the disease (moderate-to-severe patients). Thus, the 
pulmonary infection and the related symptoms (dyspnea, fever) would be more prevalent in 
moderate-to-severe patients. Currently, there is no Asian study that analyzed the data of mild-to-
moderate patients, who are however more numerous than the hospitalized patients. Second, as 
proposed by Li et al. [15] and Forster et al.[4], the differences between both world regions, 
especially about olfactory and gustatory dysfunctions, could be related to differences in the 
genetic pattern of virus (potential mutations). Third, the well-established polymorphism in the 
angiotensin converting enzyme 2 (ACE2) expression in the human tissues may also explain 
clinical differences [16]. A recent comparison of the 15 expression quantitative trait loci (eQTLs) 
variants of the ACE2 gene suggested different ACE2 polymorphisms and expression levels 
between Asian and European populations [17]. 
The clinical presentation seems to be influenced by the sex. Our data may corroborate the 
researches demonstrating the differences between males and females in the immune response to 
Covid-19 infection and inflammatory diseases. Thus, it seems that females, compared to males, 
are less susceptible to have complications related to viral infections based on a different innate 
immunity, steroid hormones and factors related to sex chromosomes [18]. Precisely, the immune 
regulatory genes encoded by female X chromosome may cause lower viral load levels, and, 
therefore, less inflammation compared with male patients [18]. Our data revealed that gender 
differences may particularly concern the development of olfactory dysfunction. Females are more 
susceptible to develop post-infectious olfactory dysfunction in viral infections related to 
parainfluenza, Epstein-Barr virus or previous form of coronavirus [19]. 
The different patterns of development and recovery of gustatory and olfactory dysfunctions found 
in our cohort rejects the hypothesis that reported loss of taste would reflect only loss of flavor due A
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to olfactory dysfunction, and suggests true gustatory dysfunction. Olfactory and gustatory 
disorders could be related to the SARS-CoV-2 neuroinvasive potential [20], which may be more 
prevalent in European patients due to  higher ACE2 expression in nasal mucosa [21]. 
Regarding treatment, our data showed that analgesics were the most commonly used drugs. Non-
steroidal drugs (NDAIDs) were not used often, perhaps reflecting early thoughts that ibuprofen 
may exacerbate disease severity. However, the published evidence for or against the use of 
NSAIDs in Covid-19 patients are currently lacking [22]. Interestingly, hydroxychloroquine was 
empirically prescribed in 12% of patients despite a lack of large randomized controlled data 
demonstrating efficacy. 
The present study has several limitations. First, our patiens were young and had few 
comorbidities. The lack of studies focusing on mild-to-moderate Covid-19 patients limits the 
comparison with the current literature. The comorbidity rates of some Asian studies focusing on 
all types of hospitalized patients is slightly higher to ours [23]. Second, as for many other studies, 
the lack of sensitivity of RT-PCR and the potential country-related differences in the indications 
for performing swabs may lead to a selection bias. Furthermore, we are reliant on self-reported 
reduction in loss of taste and smell and were unable to confirm this with objective testing. Third, 
we observed a high rate of health care workers in our population, which reflects likely exposure to 
the infection without protective material (e.g. FFP2/3 masks) in many places. While the proportion 
in our study suggests high rates of infection in health care workers than the study of Guan et al., 
[23] we are unable to provide true estimates of incidence. Fourth, regarding the lack of tests in 
Europe, it is probable that some swabs have been realized in moderate or –at risk- patients in some 
European centers, which may consist of another selection bias. 
It seems important to emphasise that this study does not assume the prevalence of Covid-19 in the 
European population, which is still unknown, but aimed to describe the clinical characteristics of 
mild-to-moderate Covid-19 patients, defined as patients who did not require hospitalization in 
intensive care units. Considering the patients of intensive care units, the prevalence of some 
symptoms, such as fever or dyspnea, would be higher. According to the clinical observation of 
many investigators of the present study, future studies would focus on the clinical presentation of 
patients regarding their disease severity. Thus, it would be possible that loss of smell may be more 
frequent in mild-to-moderate patients, especially younger and female patients, compared with 
severe forms where cough and fever are more common. Future epidemiological are needed to 
elucidate this point. A
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Conclusion
The clinical presentation of mild-to-moderate Covid-19 substantially varies according to the age 
and the sex characteristics of patients. Olfactory dysfunction seems to be an important 
underestimated symptom of mild-to-moderate Covid-19 infection since the majority of studies 
focused on hospitalized patients. Loss of smell needs to be recognized as such by the WHO. 
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Table 1: Epidemiological and Clinical Characteristics of Patients. 
Characteristic All patients Cured patients 15-39 yo 40-59 yo >60 yo
(N=1420) (N=264) (N=793) (N=551) (N=76)
Age      
  Mean (SD) - yo 39.17 ± 12.09 34.1 ± 12.4 30.14 ± 4.8 48.4 ± 5.5 66.9 ± 6.9
Gender (N - %)      
  Male 458 (32.3) 168 (63.6) 231 (29.0) 190 (34.5) 37 (48.7)
  Female 962 (67.7) 96 (36.4) 562 (71.0) 361 (65.5) 39 (51.3)
Ethnicity (N - %)
  European/Caucasian 1298 (91.4) 242 (91.7) 715 (90.2) 512 (92.9) 71 (93.4)
  Asian 11 (0.8) 1 (0.4) 6 (0.8) 5 (0.9) 0 (0)
  Black African 25 (1.8) 3 (1.1) 17 (2.1) 7 (1.3) 1 (1.3)
  North African 41 (2.9) 15 (5.7) 27 (3.4) 12 (2.2) 2 (2.6)
  North American 2 (<0.1) 1 (0.4) 2 (0.3) 0 (0) 0 (0)
  South American 37 (2.6) 1 (0.4) 24 (3.0) 13 (2.4) 0 (0)
  Oceanian 1 (<0.1) 1 (0.4) 0 (0) 0 (0) 1 (1.3)
  Mixing 5 (0.4) 0 (0) 2 (0.3) 2 (0.4) 1 (1.3)
Addictions (N - %)      
  Non-smoker 1,217 (85.7) 224 (84.8) 670 (84.4) 485 (87.8) 62 (81.6)
  Mild smoker (1-10 cigarettes daily) 162 (11.4) 40 (15.2) 98 (12.4) 53 (9.6) 11 (14.5)
  Moderate smoker (11-20 cigarettes daily) 36 (2.5) 2 (0.8) 21 (2.8) 12 (2.4) 3 (3.9)
  Heavy smoker (>20 cigarettes daily) 5 (0.4) 0 (0) 4 (0.4) 1 (0.2) 0 (0)
Allergic patients 277 (19.5) 39 (14.8) 155 (19.5) 111 (20.1) 11 (14.5)
Symptoms (N - %)
  Headache 998 (70.3) 162 (61.4) 574 (72.4) 385 (69.9) 39 (51.4)
  Loss of smell 997 (70.2) 168 (63.6) 600 (75.8) 367 (66.6) 30 (39.5)
  Nasal obstruction 963 (67.8) 157 (59.5) 585 (73.8) 335 (60.8) 43 (56.6)
  Asthenia 514 (63.3)* 200 (76.0)* 264 (59.7)* 215 (65.7)* 35 (81.4)*
  Cough 897 (63.2) 146 (55.3) 501 (63.2) 350 (63.5) 46 (60.5)
  Myalgia 887 (62.5) 154 (58.3) 480 (60.5) 370 (67.2) 37 (48.7)
  Rhinorrhea 854 (60.1) 141 (53.4) 507 (63.9) 304 (55.2) 43 (56.6)
  Taste dysfunction 770 (54.2) 107 (40.5) 434 (54.9) 298 (54.1) 38 (50.0)
  Sore throat 751 (52.9) 118 (44.7) 440 (55.5) 281 (51.0) 30 (39.5)
  Dyspnea 697 (49.1) 116 (43.9) 392 (49.4) 271 (49.2) 34 (44.7)
  Postnasal drip 680 (47.9) 105 (39.8) 398 (50.2) 254 (46.1) 28 (36.8)
  Loss of appetite 649 (45.7) 121 (45.8) 344 (43.4) 257 (46.6) 48 (63.2)
  Fever (>38C) 645 (45.4) 135 (51.1) 330 (41.6) 263 (47.7) 52 (68.4)A
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  Face pain/heaviness 644 (45.4) 82 (31.1) 393 (49.6) 232 (42.1) 19 (25.0)
  Arthralgia 519 (36.5) 74 (28.0) 265 (33.4) 226 (41.0) 28 (36.8)
  Diarrhea 473 (38.1) 90 (34.1) 253 (31.9) 184 (33.4) 36 (47.4)
  Dysphonia 176 (28.4)* 74 (28.0) 80 (23.8)* 86 (32.2)* 10 (28.6)*
  Chest pain 173 (27.2)* 72 (27.4) 85 (25.4)* 81 (5.5)* 7 (20.0)*
  Ear pain 358 (25.2) 45 (17.0) 214 (27.0) 133 (24.1) 11 (14.5)
  Dysphagia 274 (19.3) 39 (14.8) 163 (20.6) 97 (17.6) 14 (18.4)
  Nausea, vomiting 272 (19.2) 46 (17.4) 143 (18.0) 109 (19.8) 20 (26.3)
  Abdominal pain 270 (19.1) 40 (15.2) 140 (17.7) 112 (20.3) 18 (23.7)
  Reduction of smell 201 (14.2) 40 (15.2) 99 (12.6) 86 (15.6) 16 (21.1)
  Sticky mucus/phlegm 193 (15.6) 16 (6.1) 112 (14.1) 68 (12.3) 13 (17.1)
Comorbidities      
  Diabetes 24 (1.7) 4 (1.5) 2 (0.3) 15 (2.72) 7 (9.2)
  Hypertension 131 (9.2) 28 (10.6) 12 (1.5) 87 (15.8) 32 (42.1)
  CRS with or without polyps 35 (2.5) 6 2.3) 12 (1.5) 22 (4.0) 1 (1.3)
  History of Surgery for CRS 23 (1.6) 3 (1.1) 10 (1.3) 9 (1.6) 4 (5.3)
  Hypothyroidism (treated) 79 (5.6) 17 (6.4) 31 (3.9) 42 (7.6) 6 (7.9)
  Hypothyroidism (untreated) 8 (<0.1) 0 (0) 1 (0.1) 7 (1.3) 0 (0)
  Allergic rhinitis 190 (13.4) 35 (13.3) 111 (14.0) 71 (12.9) 8 (10.5)
  Renal failure 6 (0.4) 0 (0) 1 (0.1) 3 (0.5) 4 (5.3)
  Hepatic insufficiency 8 (0.6) 0 (0) 0 (0) 4 (0.7) 4 (5.3)
  Respiratory insufficiency 10 (0.7) 2 (0.8) 1 (0.1) 4 (0.7) 5 6.6)
  GERD 58 (6.9)* 20 (8.6)* 15 (3.3)* 36 (10.4)* 7 (13.7)*
  Asthma 93 (6.5) 12 (4.5) 46 (5.8) 44 (7.99) 3 (3.9)
  Heart problems 25 (1.8) 5 (1.9) 7 (0.9) 10 (1.8) 8 (10.5)
  Neurological diseases 13 (0.9) 0 (0) 3 (0.4) 4 (0.7) 6 (7.9)
  Depression 36 (2.5) 7 (2.7) 17 (2.1) 15 (2.7) 4 (5.3)
  Autoimmune diseases 18 (1.3) 2 (0.8) 5 (0.7) 8 (1.5) 5 (6.6)
  Untreated cancer/cancer under treatment 22 (1.5) 3 (1.1) 9 (1.1) 11 (2.0) 22 (28.9)
Table 1 footnotes: *Some data was not available, and, therefore, the proportion was calculated on 
a reduced sample. Abbreviations: CRS=chronic rhinosinusitis; GERD=gastroesophageal reflux 
disease; SD=standard deviation. 
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Figure 1: Symptom Proportion
Figure 1 footnotes: The proportion of symptoms (%) in the European Mild-to-moderate COVID-
19 population. 
Figure 2: Symptom Duration Data. 
Figure 2 footnotes: The proportion of patients (Y-axis) and the duration of the disease (X-axis, 
Days).
Figure 3: Overview of one Network. 
Figure 3 footnotes: Network describing the association between symptoms and some 
demographic data. 
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